Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Update

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) was the recipient of a large drop in short interest in the month of December. As of December 31st, there was short interest totalling 125,200 shares, a drop of 41.2% from the December 15th total of 212,900 shares. Based on an average trading volume of 239,400 shares, the days-to-cover ratio is currently 0.5 days.

Institutional Trading of Enlivex Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Armistice Capital LLC bought a new stake in Enlivex Therapeutics in the second quarter valued at about $2,415,000. Sigma Investment Counselors Inc. bought a new stake in Enlivex Therapeutics in the third quarter valued at about $50,000. Finally, XTX Topco Ltd bought a new stake in Enlivex Therapeutics in the second quarter valued at about $35,000. Institutional investors own 1.02% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on ENLV. D. Boral Capital restated a “buy” rating and set a $13.00 price objective on shares of Enlivex Therapeutics in a report on Wednesday, December 11th. HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of Enlivex Therapeutics in a report on Friday, September 27th.

Enlivex Therapeutics Trading Down 0.9 %

NASDAQ ENLV traded down $0.01 on Tuesday, reaching $1.14. The company’s stock had a trading volume of 86,081 shares, compared to its average volume of 99,385. The firm has a market cap of $24.40 million, a PE ratio of -1.16 and a beta of 1.00. The business has a 50-day moving average price of $1.17 and a 200 day moving average price of $1.32. Enlivex Therapeutics has a 52 week low of $0.81 and a 52 week high of $4.59.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.